Medical Aspects of Chemical Warfare (2008) - The Black Vault
Medical Aspects of Chemical Warfare (2008) - The Black Vault Medical Aspects of Chemical Warfare (2008) - The Black Vault
Incapacitating Agents126. Sidell FR. Use of Physostigmine by the Intravenous, Intramuscular, and Oral Routes in the Therapy of Anticholinergic DrugIntoxication. Biomedical Laboratory, EB-TR-76-12. Edgewood Arsenal, Md. 1976.127. Daunderer M. Physostigmine salicylate as an antidote. Int J Clin Pharmacol Ther Toxicol. 1980;18:523–535.128. Heiser JF, Gillin JC. The reversal of anticholinergic drug-induced delirium and coma with physostigmine. Am J Psychiatry.1971;127:1050–1054.129. Ghoneim MM. Antagonism of diazepam by physostigmine. Anesthesiology. 1980;52:372–373.130. Ketchum JS. Unpublished observation. Fort Benning, GA, 1975.131. Oguchi K, Arakawa K, Nelson SR, Samson F. The influence of droperidol, diazepam, and physostigmine on ketamineinducedbehavior and brain regional glucose utilization in rat. Anesthesiology. 1982;57:353–358.132. Directorate of Medical Research. Guide to the Management of BZ Casualties. Edgewood Arsenal, Md: Chemical Researchand Development Laboratory; 1965.133. Dolmierski R, Smoczynski S. Studies on the therapeutic value of atropine coma. Pol Med Sci Hist Bull. 1963;6:64–67.134. Bliss CI. The Statistics of Bioassay. New York, NY: Academic Press; 1952.135. Da Costa M. On irritable heart; a clinical study of a form of functional cardiac disorder and its consequences. Am JMed Sci. 1971;61:17–52.136. US Department of the Army. Flame, Riot control Agents, and Herbicide Operations. Washington, DC: DA, 1996: 1–4. FM3-11.137. Office of Under Secretary of Defense for Acquisition, Technology, and Logistics. Treaty compliance: CCW: article byarticle analysis of the protocol on blinding laser weapons. ACQWeb Web site. Available at: http://www.defenselink.mil/acq/acic/treaties/ccwapl/artbyart_pro4.htm. Accessed January 3, 2006.138. Stanton MN. What price sticky foam? Parameters. 1996;Autumn:63–68.139. The Sunshine Project. Non-lethal weapons research in the US: calmatives and malodorants. Sunshine Project Web site.Available at: http://www.sunshine-project.org/publications/bk/bk8en.html. Accessed January 5, 2006.140. Alexander J. Future War: Non-lethal Weapons in Modern Warfare. New York, NY: St Martin’s Press; 1999.439
Medical Aspects of Chemical Warfare440
- Page 411 and 412: Medical Aspects of Chemical Warfare
- Page 413 and 414: Medical Aspects of Chemical Warfare
- Page 415 and 416: Medical Aspects of Chemical Warfare
- Page 417 and 418: Medical Aspects of Chemical Warfare
- Page 419 and 420: Medical Aspects of Chemical Warfare
- Page 421 and 422: Medical Aspects of Chemical Warfare
- Page 423 and 424: Medical Aspects of Chemical Warfare
- Page 425 and 426: Medical Aspects of Chemical Warfare
- Page 427 and 428: Medical Aspects of Chemical Warfare
- Page 429 and 430: Medical Aspects of Chemical Warfare
- Page 431 and 432: Medical Aspects of Chemical Warfare
- Page 433 and 434: Medical Aspects of Chemical Warfare
- Page 435 and 436: Medical Aspects of Chemical Warfare
- Page 437 and 438: Medical Aspects of Chemical Warfare
- Page 439 and 440: Medical Aspects of Chemical Warfare
- Page 441 and 442: Medical Aspects of Chemical Warfare
- Page 443 and 444: Medical Aspects of Chemical Warfare
- Page 445 and 446: Medical Aspects of Chemical Warfare
- Page 447 and 448: Medical Aspects of Chemical Warfare
- Page 449 and 450: Medical Aspects of Chemical Warfare
- Page 451 and 452: Medical Aspects of Chemical Warfare
- Page 453 and 454: Medical Aspects of Chemical Warfare
- Page 455 and 456: Medical Aspects of Chemical Warfare
- Page 457 and 458: Medical Aspects of Chemical Warfare
- Page 459 and 460: Medical Aspects of Chemical Warfare
- Page 461: Medical Aspects of Chemical Warfare
- Page 465 and 466: Medical Aspects of Chemical Warfare
- Page 467 and 468: Medical Aspects of Chemical Warfare
- Page 469 and 470: Medical Aspects of Chemical Warfare
- Page 471 and 472: Medical Aspects of Chemical Warfare
- Page 473 and 474: Medical Aspects of Chemical Warfare
- Page 475 and 476: Medical Aspects of Chemical Warfare
- Page 477 and 478: Medical Aspects of Chemical Warfare
- Page 479 and 480: Medical Aspects of Chemical Warfare
- Page 481 and 482: Medical Aspects of Chemical Warfare
- Page 483 and 484: Medical Aspects of Chemical Warfare
- Page 485 and 486: Medical Aspects of Chemical Warfare
- Page 487 and 488: Medical Aspects of Chemical Warfare
- Page 489 and 490: Medical Aspects of Chemical Warfare
- Page 491 and 492: Medical Aspects of Chemical Warfare
- Page 493 and 494: Medical Aspects of Chemical Warfare
- Page 495 and 496: Medical Aspects of Chemical Warfare
- Page 497 and 498: Medical Aspects of Chemical Warfare
- Page 499 and 500: Medical Aspects of Chemical Warfare
- Page 501 and 502: Medical Aspects of Chemical Warfare
- Page 503 and 504: Medical Aspects of Chemical Warfare
- Page 505 and 506: Medical Aspects of Chemical Warfare
- Page 507 and 508: Medical Aspects of Chemical Warfare
- Page 509 and 510: Medical Aspects of Chemical Warfare
- Page 511 and 512: Medical Aspects of Chemical Warfare
Incapacitating Agents126. Sidell FR. Use <strong>of</strong> Physostigmine by the Intravenous, Intramuscular, and Oral Routes in the <strong>The</strong>rapy <strong>of</strong> Anticholinergic DrugIntoxication. Biomedical Laboratory, EB-TR-76-12. Edgewood Arsenal, Md. 1976.127. Daunderer M. Physostigmine salicylate as an antidote. Int J Clin Pharmacol <strong>The</strong>r Toxicol. 1980;18:523–535.128. Heiser JF, Gillin JC. <strong>The</strong> reversal <strong>of</strong> anticholinergic drug-induced delirium and coma with physostigmine. Am J Psychiatry.1971;127:1050–1054.129. Ghoneim MM. Antagonism <strong>of</strong> diazepam by physostigmine. Anesthesiology. 1980;52:372–373.130. Ketchum JS. Unpublished observation. Fort Benning, GA, 1975.131. Oguchi K, Arakawa K, Nelson SR, Samson F. <strong>The</strong> influence <strong>of</strong> droperidol, diazepam, and physostigmine on ketamineinducedbehavior and brain regional glucose utilization in rat. Anesthesiology. 1982;57:353–358.132. Directorate <strong>of</strong> <strong>Medical</strong> Research. Guide to the Management <strong>of</strong> BZ Casualties. Edgewood Arsenal, Md: <strong>Chemical</strong> Researchand Development Laboratory; 1965.133. Dolmierski R, Smoczynski S. Studies on the therapeutic value <strong>of</strong> atropine coma. Pol Med Sci Hist Bull. 1963;6:64–67.134. Bliss CI. <strong>The</strong> Statistics <strong>of</strong> Bioassay. New York, NY: Academic Press; 1952.135. Da Costa M. On irritable heart; a clinical study <strong>of</strong> a form <strong>of</strong> functional cardiac disorder and its consequences. Am JMed Sci. 1971;61:17–52.136. US Department <strong>of</strong> the Army. Flame, Riot control Agents, and Herbicide Operations. Washington, DC: DA, 1996: 1–4. FM3-11.137. Office <strong>of</strong> Under Secretary <strong>of</strong> Defense for Acquisition, Technology, and Logistics. Treaty compliance: CCW: article byarticle analysis <strong>of</strong> the protocol on blinding laser weapons. ACQWeb Web site. Available at: http://www.defenselink.mil/acq/acic/treaties/ccwapl/artbyart_pro4.htm. Accessed January 3, 2006.138. Stanton MN. What price sticky foam? Parameters. 1996;Autumn:63–68.139. <strong>The</strong> Sunshine Project. Non-lethal weapons research in the US: calmatives and malodorants. Sunshine Project Web site.Available at: http://www.sunshine-project.org/publications/bk/bk8en.html. Accessed January 5, 2006.140. Alexander J. Future War: Non-lethal Weapons in Modern <strong>Warfare</strong>. New York, NY: St Martin’s Press; 1999.439
Change language